FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer

Inclusion Criteria: * Age 18 years or older * Willing and able to provide written informed consent * Unequivocal and measurable CT evidence of liver metastases which are not treatable by surgical resection or local ablation * Limited extra-hepatic metastases in the lung and/or lymph nodes are permitted (Lung: 5 lesions total, \< 1 cm, or 1 single lesion of up to 1.7 cm; Lymph nodules in one single anatomic area (pelvis, abdomen or chest): any number, \< 2 cm) * All imaging evidence used as part of the screening process must be within 28 days * Suitable for either treatment regimen * WHO performance status 0-1 * Adequate hematological, renal and hepatic function * Life expectancy of at least 3 months without any active treatment Exclusion Criteria: * Evidence of ascites, cirrhosis, portal hypertension, main portal or venous involvement or thrombosis as determined by clinical or radiologic assessment * Previous radiotherapy delivered to the liver * Non-malignant disease that would render the patient unsuitable for treatment according to the protocol * Peripheral neuropathy \> grade 2 (NCI-CTC) * Dose-limiting toxicity associated with previous adjuvant 5-FU or oxaliplatin chemotherapy * Prior non-adjuvant chemotherapy for any malignancy. Adjuvant chemotherapy for colorectal cancer is permitted provided that it was completed more than 6 months before entry into the study * Pregnant or breast feeding * Concurrent or prior history of cancer other than adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix * Allergy to contrast media that would preclude angiography of the hepatic arteries